MMSI · Merit Medical Systems, Inc.

Merit Medical Systems, Inc. completed the acquisition of View Point Medical, Inc. on April 1, 2026, through a merger that integrates View Point as a wholly-owned subsidiary. The deal, valued at approximately $140 million including assumed liabilities, involved $90 million in cash at closing and two $25 million deferred payments due on the first and second anniversaries. This transaction bolsters Merit's leadership in wire-free, non-radioactive breast localization procedures by adding View Point's FDA-cleared OneMark Detection Imaging System and tissue markers, which enhance ultrasound visibility during biopsies. CEO Martha G. Aronson highlighted the expansion of Merit's therapeutic oncology portfolio, targeting an estimated 1.3 million annual US procedures and complementing the SCOUT platform to potentially reduce secondary localization surgeries. Chief Commercial Officer Adam Smith emphasized early localization benefits amid evolving treatment protocols. Financially, the acquisition is expected to contribute $2-4 million in revenue through December 31, 2026, with $0.05 dilution to non-GAAP EPS after interest income impacts but before $5.3 million in transaction expenses. In 2027, revenue is projected at $14-16 million, turning accretive to non-GAAP EPS with 70% gross margins and positive operating margin contributions, while remaining dilutive to GAAP metrics initially. Sales growth for OneMark is forecasted at least 20% annually. Piper Sandler & Co. advised financially, and Baker & McKenzie LLP provided legal counsel. Further details will be discussed on the Q1 investor call on April 30, 2026.